Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Michal Oren
Observed names:
M. Oren,
Michal Yalan Oren,
Michal Yalon Oren
Institution:
Sheba Medical Center
Observed institutions:
Mayo Clinic,
Tel Aviv University,
Tel Aviv Sourasky Medical Center,
Sheba Medical Center,
Wolfson Medical Center,
University of Pennsylvania
show all 6
OpenAlex ID:
A5078666991
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial
2023
·
Lindsay B. Kilburn
, Dong-Anh Khuong-Quang
, et al.
·
Nature Medicine
·
215
PDF
Compensation of Coulomb Blocking and Energy Transfer in the Current Voltage Characteristic of Molecular Conduction Junctions
2012
·
Guangqi Li
, Manmohan S. Shishodia
, et al.
·
Nano Letters
·
38
PDF
Outcomes of Infants and Young Children With Relapsed Medulloblastoma After Initial Craniospinal Irradiation–Sparing Approaches: An International Cohort Study
2022
·
Craig Erker
, Martin Mynarek
, et al.
·
Journal of Clinical Oncology
·
33
Raman scattering from molecular conduction junctions: Charge transfer mechanism
2012
·
Michal Oren
, Michael Galperin
, et al.
·
Physical Review B
·
32
Transradial versus Transfemoral Approach in Peripheral Arterial Interventions
2015
·
Michal Oren
, Yoav Turgeman
, et al.
·
International Journal of Angiology
·
19
PDF
Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial
2024
·
Karsten Nysom
, Lindsay B Kilburn
, et al.
·
Neuro-Oncology
·
14
PDF
Permanent lone atrial fibrillation and atrioventricular valve regurgitation: may the former lead to the latter?
2014
·
Michal Oren
, Ohad Oren
, et al.
·
PubMed
·
13
Ctni-68. Firefly-1 (pnoc026): Phase 2 Study of Pan-raf Inhibitor Tovorafenib in Pediatric and Young Adult Patients With Raf-altered Recurrent or Progressive Low-grade Glioma or Advanced Solid Tumors
2022
·
Lindsay Kilburn
, Daniel Landi
, et al.
·
Neuro-Oncology
·
11
PDF
Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial
2024
·
Lindsay B. Kilburn
, Dong-Anh Khuong-Quang
, et al.
·
Nature Medicine
·
6
PDF
On the generalizability of prostate cancer studies: why race matters
2016
·
O. Oren
, M. Oren
, et al.
·
Annals of Oncology
·
6
Trls-14. Pnoc022 Report: a Combination Therapy Trial Using an Adaptive Platform Design for Patients With Diffuse Midline Glioma at Initial Diagnosis, Post-radiation Therapy, or Progression
2024
·
Cassie Kline
, Andrea Franson
, et al.
·
Neuro-Oncology
·
3
The use of cardiovascular disease states as exclusion criteria in breast cancer trials: A 4-decade perspective.
2017
·
Michal Oren
, Ohad Oren
, et al.
·
Journal of Clinical Oncology
·
3
Ctni-09. Type Ii Raf Inhibitor Tovorafenib in Relapsed/refractory (r/r) Pediatric Low-grade Glioma (plgg): Results From Patients on a Drug Holiday (dh) in the Phase 2 Firefly-1 Trial
2024
·
Sébastien Perreault
, Dong-Anh Khuong-Quang
, et al.
·
Neuro-Oncology
·
2
PDF
Ctni-24. Clinical Activity and Safety of the Raf Inhibitor Tovorafenib in Patients With Optic Pathway Gliomas in the Registrational Pediatric Low-grade Glioma Arm of the Phase 2 Firefly-1 (pnoc026) Study
2023
·
Karsten Nysom
, Lindsay Kilburn
, et al.
·
Neuro-Oncology
·
2
PDF
Ctni-84. Pnoc022: a Combination Therapy Trial Using an Adaptive Platform Design for Patients With Diffuse Midline Gliomas (dmgs) at Initial Diagnosis, Post-radiation Therapy and at Time of Progression
2023
·
Cassie Kline
, Andrea Franson
, et al.
·
Neuro-Oncology
·
2
PDF
Cost Effectiveness of an Outcome Based Reimbursement Model of Pcsk9 Inhibitors
2018
·
Ohad Oren
, Michal Oren
·
Journal of the American College of Cardiology
·
2
PDF
Lgg-40. Type Ii Raf Inhibitor Tovorafenib in Relapsed/refractory Pediatric Low-grade Glioma (plgg): Reversible Decreases in Growth Velocity in the Phase 2 Firefly-1 Trial
2024
·
Cassie Kline
, Angela J Waanders
, et al.
·
Neuro-Oncology
·
1
Immu-18. Favorable Outcome in Replication Repair Deficient Hypermutant Brain Tumors to Immune Checkpoint Inhibition: an International Rrd Consortium Registry Study
2020
·
Eric Bouffet
, Sumedha Sudhaman
, et al.
·
Neuro-Oncology
·
1
PDF
Abstract 12820: Beta Blocker Use and Peri-operative Outcomes in Cancer Patients Receiving Immunotherapy
2020
·
Ohad Oren
, Julian R Molina
, et al.
·
Circulation
·
1
Clinical Trials of Cardiotoxicity in Breast Cancer
2017
·
Ohad Oren
, Michal Oren
·
Journal of the American College of Cardiology
·
1
PDF
Clinical stability after tovorafenib treatment in patients with relapsed/refractory pediatric low-grade glioma: Updated results from the phase 2 FIREFLY-1 trial
2026
·
Cassie Kline
, Daniel Landi
, et al.
·
Neuro-Oncology Pediatrics
Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial
2025
·
Lindsay B. Kilburn
, Dong-Anh Khuong-Quang
, et al.
·
Nature Medicine
PDF
Ctim-34. Effects of Neoadjuvant Immune Checkpoint Inhibition on Pediatric and Adult High-grade Gliomas
2024
·
Hadar Keren-Gill
, Gilbert Herrera
, et al.
·
Neuro-Oncology
PDF
Ncog-05. Health-related Quality of Life (hrqol) in the Phase 2 Firefly-1 (pnoc026) Trial of the Type Ii Raf Inhibitor Tovorafenib in Relapsed/refractory (r/r) Pediatric Low-grade Glioma (plgg)
2024
·
John (Devin) Peipert
, Patricia A Baxter
, et al.
·
Neuro-Oncology
PDF
Impact of a Single-step Educational Intervention to Improve Referral to an Institutional Cardio-oncology Clinic by Hematology and Oncology Fellows
2022
·
Ohad Oren
, Michal Oren
, et al.
·
Journal of the American College of Cardiology
PDF
Show more works
View as search
Works count:
37
Citation count:
405
H-index:
8
I10-index:
8
Year
Topic
Type
